Dinitrophenyl-modified melanoma cell surface proteins (DNP-melanoma proteins)

Dinitrophenyl-modified melanoma cell surface proteins represent a therapeutic target used in autologous cancer immunotherapy (Berd et al., 1986, Cancer Research). By chemically attaching the dinitrophenyl (DNP) hapten to lysine residues on the surface of a patient's own melanoma cells, the tumor proteins are rendered highly immunogenic (Manne et al., 2002, Expert Opinion on Biological Therapy). This modification is designed to overcome the immune system's tolerance to tumor-associated antigens by creating a foreign appearance that triggers a robust T-cell mediated immune response (Berd et al., 1991, Journal of Clinical Oncology). When administered as a vaccine, these haptenized proteins stimulate the production of cytotoxic T lymphocytes that can recognize and attack both the modified and unmodified melanoma cells throughout the body (Sato et al., 2003, Clinical Cancer Research). This approach has been primarily investigated in the treatment of metastatic melanoma to prevent recurrence and induce regression of existing lesions (Berd et al., 2004, Journal of Clinical Oncology). The treatment typically involves a priming dose of cyclophosphamide to deplete suppressor T cells followed by multiple injections of the DNP-modified cells (Berd et al., 1997, Seminars in Oncology). Clinical trials have demonstrated that patients who develop a strong delayed-type hypersensitivity (DTH) response to the modified cells have significantly improved survival outcomes (Berd et al., 1991, Journal of Clinical Oncology). This target is unique because it utilizes the entire repertoire of a patient's tumor antigens rather than a single specific protein (Manne et al., 2002, Expert Opinion on Biological Therapy).

Other names

DNP-haptenized melanoma antigensDNP-modified autologous melanoma cellsDNP-lysine-modified tumor proteinsM-Vax targetDNP-VACC

Haptenization of tumor cell surface proteins with dinitrophenyl (DNP) increases the immunogenicity of weakly antigenic tumor proteins (Berd et al., 1986, Cancer Research). The DNP group acts as a foreign epitope that, when conjugated to lysine residues of tumor proteins, facilitates the recruitment of T-helper cells and breaks immunological tolerance, leading to a cytotoxic T-lymphocyte response against the underlying tumor antigens (Manne et al., 2002, Expert Opinion on Biological Therapy).